Glaukos Corporation (GKOS) News
Follow Glaukos Corporation (GKOS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 45 public stories across 17 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
NYSE Reports Sell-Side Order Imbalance of 1,061,376 Shares
EQUITY | Nov 03, 2026, 08:50 PM UTC
M
Okta to Join S&P 500, Replacing Kenvue
Okta was selected for inclusion in the S&P 500, replacing Kenvue.
EQUITY | Nov 02, 2026, 05:31 PM UTC
M
Okta Set to Replace Kenvue in S&P 500 Index
Okta is set to replace Kenvue in the S&P 500, according to the report.
EQUITY | Nov 02, 2026, 05:31 PM UTC
M
Glaukos Raises 2026 Net Sales Guidance to $77
Glaukos raised its 2026 net sales guidance to $77; the supplied text provides no unit or further details.
EQUITY | Oct 29, 2026, 11:17 PM UTC
L
NYSE Reports 178291.0-Share Buy-Side Order Imbalance
EQUITY | Oct 29, 2026, 07:50 PM UTC
M
Glaukos Shares Rise More Than 32% After Q3 Beat and Raised Guidance
Glaukos shares were up more than 32% in Thursday trading after a third-quarter earnings beat and raised guidance.
EARNINGS | Oct 29, 2026, 07:04 PM UTC
M
Glaukos shares soar 31% amid heavy trading
Glaukos shares rose 31% amid heavy trading.
EQUITY | Oct 29, 2026, 05:30 PM UTC
M
Median Technologies Q3 Revenue Reaches Record High
France-based medical imaging firm Median Technologies reported record-high revenue for the third quarter.
EQUITY | Oct 29, 2026, 04:57 PM UTC
M
Glaukos Shares Touch Record High After Surprise Profit
Glaukos shares touched a record high after the company posted a surprise profit.
EARNINGS | Oct 29, 2026, 04:35 PM UTC
M
Glaukos Shares Surge 30% After Earnings, Near Record Close
Glaukos shares climbed 30% to $236.64 on Thursday, putting them on track for a record closing high after a blowout quarter and a pathway to $1 billion in annual sales.
EQUITY | Oct 29, 2026, 03:57 PM UTC
M
Glaukos shares extend gains, up 23.0%
EQUITY | Oct 29, 2026, 01:44 PM UTC
M
Glaukos Shares Jump 18% Premarket After Q3 Profit
Glaukos shares rose 18% premarket after the company reported a surprise third-quarter profit.
EQUITY | Oct 29, 2026, 08:40 AM UTC
M
GKOS Reports FY2026 Q3 Net Loss
GKOS reported a net loss attributable to shareholders for the third quarter of fiscal 2026, up 33.11% year over year. Basic EPS was negative.
EQUITY | Oct 29, 2026, 08:37 AM UTC
M
Glaukos Raises Annual Net Sales Outlook; Shares Jump 18%
Glaukos issued higher net sales guidance for the year. Shares rose almost 18% after the bell to $213.90.
EARNINGS | Oct 28, 2026, 10:43 PM UTC
M
Glaukos Raises 2026 Net Sales Guidance to $775 Million–$785 Million
Glaukos now expects full-year 2026 net sales of $775 million to $785 million, above the FactSet consensus estimate of $691.7 million.
EARNINGS | Oct 28, 2026, 10:03 PM UTC
M
Glaukos Reports Third-Quarter Revenue of $211 Million, Net Income of $2 Million
Glaukos reported third-quarter 2026 diluted EPS of $0.03, compared with a loss of $0.28 a year earlier. Revenue rose 58% from $133.5 million, while net income compared with a prior-year net loss of $16.2 million.
EQUITY | Oct 28, 2026, 09:31 PM UTC
M
Glaukos Swings to Q3 2026 Net Income of $2.02 Million; Sales Rise 58%
Glaukos reported Q3 2026 net income of $2.02 million, compared with a year-earlier loss, while net sales rose 58% year over year to $211.03 million.
EARNINGS | Oct 28, 2026, 08:31 PM UTC
M
Glaukos posts Q3 adjusted EPS of $0.47 per share
Glaukos reported Q3 adjusted EPS of $0.47 per share, versus a FactSet estimate of $-0.10.
EARNINGS | Oct 28, 2026, 08:10 PM UTC
M
Glaukos reports third-quarter net income of $2.02 million
EARNINGS | Oct 28, 2026, 08:07 PM UTC
M
Glaukos Reports 3Q Sales of $211M
EARNINGS | Oct 28, 2026, 08:07 PM UTC
M
Glaukos Announces Third-Quarter 2026 Financial Results
Glaukos reported financial results for the quarter ended September 30, 2026.
EQUITY | Oct 28, 2026, 08:06 PM UTC
H
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Ophthalmic pharmaceutical and medical technology firm Glaukos Corporation (NYSE: GKOS ) reported successful topline outcomes from its latest Phase 4 clinical study. The trial evaluated the effectiveness of administering
LIVE | Oct 09, 2026, 04:49 PM UTC
H
BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling around 1% on Wednesday. Shares of BKV Corp (NYSE: BKV ) rose sharply after the company announced that a subsidiary executed into a n equipment supply contract. BKV
LIVE | Oct 07, 2026, 02:08 PM UTC
M
Glaukos to release Q3 2026 results on Oct. 28
Glaukos said it will release third-quarter 2026 financial results after market close on October 28.
EQUITY | Oct 07, 2026, 11:10 AM UTC
L
GKOS - Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
GKOS - Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
NEWS | Sep 23, 2026, 11:05 AM UTC
L
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the launch
NEWS | Sep 23, 2026, 11:00 AM UTC
L
Epioxa and iDose drive growth as GKOS expands access and pipeline
Epioxa’s commercial launch is progressing as payer access expands and Photrexa sunset continues. iDose and core MIGS businesses are growing, with a pipeline and new screening device supporting future expansion, as manage
EQUITY | Sep 09, 2026, 08:37 PM UTC
L
Epioxa and iDose drive growth as payer access expands and milestones approach
Epioxa’s commercial launch is progressing as payer access expands and Photrexa has been sunset. iDose continues to grow with strong Medicare Advantage uptake, while the pipeline advances with multiple clinical milestones
EQUITY | Sep 09, 2026, 08:01 PM UTC
L
Glaukos (GKOS) to Participate in Wells Fargo Healthcare Conference
Glaukos (GKOS) announces its participation in a Wells Fargo Healthcare Conference, according to TradeXchange Newsdesk.
EQUITY | Aug 19, 2026, 11:03 AM UTC
L
GKOS PT raised from $180 to $215, maintains Buy @ Truist
GKOS PT raised from $180 to $215, maintains Buy @ Truist
EQUITY | Jul 30, 2026, 12:31 PM UTC
L
GKOS Q2 Scraped: adj. EPS $(0.14) vs. est. $(0.22), revenue $185.6Mm vs. est. $151.0Mm, adj. gross margin 85%; FY26 sales guidance raised to
GKOS Q2 Scraped: adj. EPS $(0.14) vs. est. $(0.22), revenue $185.6Mm vs. est. $151.0Mm, adj. gross margin 85%; FY26 sales guidance raised to $680Mm—$700Mm vs. est. $629.98Mm; shares +8.3%
EARNINGS | Jul 29, 2026, 08:38 PM UTC
H
PRCH +20%, CORT +18.3%, BOOM +17.3%, FORM +16.4%, SBUX +10.2%, FTNT +9.4%, BHE +9.3%, LUNG +8.8%, LRCX +7.6%, CMG +7.1%, GKOS +7%, GFL +5.7%
PRCH +20%, CORT +18.3%, BOOM +17.3%, FORM +16.4%, SBUX +10.2%, FTNT +9.4%, BHE +9.3%, LUNG +8.8%, LRCX +7.6%, CMG +7.1%, GKOS +7%, GFL +5.7%, RGR 4.8%, MOD +3.9%, ICLR +3.8%, ST +3.6%, MAX +2.6%, EQIX +2.4% after results
EARNINGS | Jul 29, 2026, 08:27 PM UTC
L
Glaukos Raises FY2026 Sales Guidance from $620.000M-$635.000M to $680.000M-$700.000M vs $629.748M Est
Glaukos (NYSE: GKOS ) raises FY2026 sales outlook from $620.000 million-$635.000 million to $680.000 million-$700.000 million vs $629.748 million estimate.
EARNINGS | Jul 29, 2026, 08:17 PM UTC
L
GKOS - Glaukos Announces Second Quarter 2026 Financial Results
GKOS - Glaukos Announces Second Quarter 2026 Financial Results
EARNINGS | Jul 29, 2026, 08:13 PM UTC
L
GKOS Glaukos RESULTS: Q2, Q2 Net Income $-18.4M, Q2 ADJ Net Income $-8.3M vs. EST $-12.3M, Q2 gross margin 82%, Q2 sales $185.6M vs. EST $15
GKOS Glaukos RESULTS: Q2, Q2 Net Income $-18.4M, Q2 ADJ Net Income $-8.3M vs. EST $-12.3M, Q2 gross margin 82%, Q2 sales $185.6M vs. EST $150.9M, Q2 ADJ gross margin 85%, Glaukos Earnings Notes:, Outlook FY sales $680-70
EARNINGS | Jul 29, 2026, 08:07 PM UTC
L
RXST GKOS SGHT BLCO COO STAA Medical Supplies and Devices initiation - resuming coverage across the Vision sector (Neutral rated GKOS, Neutr
RXST GKOS SGHT BLCO COO STAA Medical Supplies and Devices initiation - resuming coverage across the Vision sector (Neutral rated GKOS, Neutral rated RXST, Buy rated SGHT) and initiating coverage of Buy rated BLCO, Neutra
EQUITY | Jul 28, 2026, 11:52 AM UTC
L
GKOS Initiated Neutral at UBS
GKOS Initiated Neutral at UBS
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
GKOS Reiterate Buy and PT $175 as Epioxa/CXL Deep Dive and Early Epioxa Adopter Survey Checks Strengthen Intermediate-to-Long-Term Bullishne
GKOS Reiterate Buy and PT $175 as Epioxa/CXL Deep Dive and Early Epioxa Adopter Survey Checks Strengthen Intermediate-to-Long-Term Bullishness @ Stifel
EQUITY | Jul 28, 2026, 11:15 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
L
GKOS d/g Neutral @ UBS
GKOS d/g Neutral @ UBS
EQUITY | Jul 28, 2026, 09:15 AM UTC
L
GKOS Reiterate Buy and raise PT $170 to $175 after iDose Survey Diligence @ Stifel
GKOS Reiterate Buy and raise PT $170 to $175 after iDose Survey Diligence @ Stifel
EQUITY | Jul 17, 2026, 11:06 AM UTC
L
Glaukos Insider Sold Shares Worth $1,550,000, According to a Recent SEC Filing
() -- Alex R. Thurman, Senior Vice President and Chief Financial Officer, on July 09, 2026, sold 10,000 shares in Glaukos (GKOS) for $1,550,000. Following the Form 4 filing with the SEC, Thurman has control over a total
GEOPOLITICS | Jul 14, 2026, 08:10 AM UTC
L
Glaukos Insider Sold Shares Worth $1,500,000, According to a Recent SEC Filing
() -- Alex R. Thurman, Senior Vice President and Chief Financial Officer, on July 06, 2026, sold 10,000 shares in Glaukos (GKOS) for $1,500,000. Following the Form 4 filing with the SEC, Thurman has control over a total
GEOPOLITICS | Jul 09, 2026, 07:06 AM UTC
L
Piper Sandler Reiterates Overweight on Glaukos, Maintains $165 Price Target
Piper Sandler analyst Adam Maeder reiterates Glaukos (NYSE: GKOS ) with a Overweight and maintains $165 price target.
EQUITY | Jul 01, 2026, 01:29 PM UTC
L
GKOS Completes Enrollment
Glaukos completes patient enrollment in Phase 2 study of GLK-321 for Demodex Blepharitis
EQUITY | Jun 25, 2026, 11:11 AM UTC